Recursion Pharmaceuticals Inc
NASDAQ:RXRX
Income Statement
Earnings Waterfall
Recursion Pharmaceuticals Inc
Revenue
|
44.6m
USD
|
Cost of Revenue
|
-42.6m
USD
|
Gross Profit
|
2m
USD
|
Operating Expenses
|
-350.8m
USD
|
Operating Income
|
-348.9m
USD
|
Other Expenses
|
20.8m
USD
|
Net Income
|
-328.1m
USD
|
Income Statement
Recursion Pharmaceuticals Inc
Sep-2021 | Dec-2021 | Mar-2022 | Jun-2022 | Sep-2022 | Dec-2022 | Mar-2023 | Jun-2023 | Sep-2023 | Dec-2023 | ||
---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | |||||||||||
Revenue |
8
N/A
|
10
+33%
|
13
+27%
|
18
+40%
|
29
+59%
|
40
+39%
|
47
+17%
|
50
+7%
|
47
-5%
|
45
-6%
|
|
Gross Profit | |||||||||||
Cost of Revenue |
0
|
0
|
(8)
|
(22)
|
(37)
|
(48)
|
(53)
|
(48)
|
(44)
|
(43)
|
|
Gross Profit |
0
N/A
|
0
N/A
|
(2)
N/A
|
(9)
-265%
|
(11)
-25%
|
(8)
+25%
|
(6)
+26%
|
2
N/A
|
4
+99%
|
2
-48%
|
|
Operating Income | |||||||||||
Operating Expenses |
(125)
|
(193)
|
(214)
|
(227)
|
(238)
|
(237)
|
(249)
|
(276)
|
(315)
|
(351)
|
|
Selling, General & Administrative |
(38)
|
(67)
|
(72)
|
(77)
|
(80)
|
(96)
|
(83)
|
(93)
|
(103)
|
(134)
|
|
Research & Development |
(87)
|
(126)
|
(141)
|
(150)
|
(157)
|
(141)
|
(166)
|
(181)
|
(207)
|
(208)
|
|
Depreciation & Amortization |
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(2)
|
(5)
|
(9)
|
|
Operating Income |
(118)
N/A
|
(183)
-55%
|
(209)
-14%
|
(231)
-10%
|
(247)
-7%
|
(246)
+0%
|
(256)
-4%
|
(274)
-7%
|
(311)
-13%
|
(349)
-12%
|
|
Pre-Tax Income | |||||||||||
Interest Income Expense |
(3)
|
(3)
|
(3)
|
1
|
3
|
6
|
11
|
15
|
18
|
19
|
|
Non-Reccuring Items |
(1)
|
(1)
|
0
|
(4)
|
(3)
|
0
|
(4)
|
(1)
|
(1)
|
(1)
|
|
Total Other Income |
(0)
|
0
|
(0)
|
(0)
|
0
|
0
|
0
|
0
|
1
|
(1)
|
|
Pre-Tax Income |
(122)
N/A
|
(186)
-53%
|
(212)
-14%
|
(234)
-10%
|
(247)
-6%
|
(239)
+3%
|
(249)
-4%
|
(260)
-4%
|
(293)
-13%
|
(332)
-14%
|
|
Net Income | |||||||||||
Tax Provision |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
4
|
|
Income from Continuing Operations |
(122)
|
(186)
|
(212)
|
(234)
|
(247)
|
(239)
|
(249)
|
(260)
|
(293)
|
(328)
|
|
Net Income (Common) |
(122)
N/A
|
(186)
-53%
|
(212)
-14%
|
(234)
-10%
|
(247)
-6%
|
(239)
+3%
|
(249)
-4%
|
(260)
-4%
|
(293)
-13%
|
(328)
-12%
|
|
EPS (Diluted) |
-0.72
N/A
|
-1.49
-107%
|
-1.24
+17%
|
-1.37
-10%
|
-1.44
-5%
|
-1.36
+6%
|
-1.29
+5%
|
-1.32
-2%
|
-1.37
-4%
|
-1.58
-15%
|